Search Within

Angemael Syldor

Formats
  1. Meeting Abstract (7)
Groups
  1. Breast Medicine Service (7)
  2. Department of Medicine (7)
  3. Solid Tumor Oncology Division (7)
  4. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (6)
  5. GSK Faculty (6)
  6. Human Oncology and Pathogenesis Program (6)

More Groups

People
  1. Sarat Chandarlapaty (6)
  2. Devika Gajria (5)
  3. Clifford Hudis (4)
  4. Pamela Drullinsky (4)
  5. Shanu Modi (4)
  6. Sujata Patil (4)

More People

Years
  1. 2024 (2)
  2. 2012 (3)
  3. 2011 (2)
Publications
  1. Journal of Clinical Oncology (4)
  2. Cancer Research (3)
Publishers
  1. American Society of Clinical Oncology (4)
  2. American Association for Cancer Research (3)

Results (7)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • TBCRC 058: A randomized phase II study of enzalutamide, enzalutamide with mifepristone, and treatment of physician's choice in patients with androgen receptor-positive metastatic triple-negative or estrogen receptor-low breast cancer (NCT06099769)
    Meeting Abstract

    Traina, T. A.; Chen, Y.; Khoury, K.; Rugo, H. S.; Mayer, E. L.; Carey, L. A.; Melisko, M. E.; Syldor, A.; Friedman, C.; Savoie, J.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Optimizing clinical research in a regional cancer center network: A survey-based approach
    Meeting Abstract

    Preeshagul, I. R.; Syldor, A.; Terzulli, S. L.; Gordon, R. A.; Evans, L. A.; Moran, S.; Eng, J.; Daly, R. M.; Rao, D.; Momtaz, P.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with HER2-overexpressing metastatic breast cancer (MBC)
    Meeting Abstract

    Datko, F. M.; D'Andrea, G.; Dickler, M. N.; Theodoulou, M.; Goldfarb, S. B.; Lake, D.; Fornier, M. N.; Modi, S.; Sklarin, N. T.; Comen, E. A.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with metastatic HER2-overexpressing metastatic breast cancer
    Meeting Abstract

    Datko, F.; D'Andrea, G.; Dickler, M.; Theodoulou, M.; Goldfarb, S.; Lake, D.; Fornier, M.; Modi, S.; Sklarin, N.; Comen, E.; more...
    Cancer Research (2012)

    Fulltext@MSK | Save
  • Tolerability and efficacy of targeting both mTOR and HER2 signaling in trastuzumab-refractory HER2+ metastatic breast cancer
    Meeting Abstract

    Gajria, D.; King, T.; Pannu, H.; Sakr, R.; Modi, S.; Drullinsky, P.; Syldor, A.; Patil, S.; Seidman, A.; Norton, L.; more...
    Cancer Research (2012)

    Fulltext@MSK | Save
  • Combined inhibition of mTORC1 with temsirolimus and HER2 with neratinib: A phase I study in patients with metastatic HER2-amplified breast cancer
    Meeting Abstract

    Gajria, D.; King, T. A.; Pannu, H.; Sakr, R.; Seidman, A. D.; Syldor, A.; Patil, S.; Maybody, M.; Norton, L.; Rosen, N.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Combined inhibition of mTORC1 with temsirolimus and HER2 with neratinib: A phase I/II study in patients with metastatic HER2-amplified or triple-negative breast cancer
    Meeting Abstract

    Gajria, D.; King, T.; Pannu, H.; Sakr, R.; Seidman, A. D.; Modi, S.; Dickler, M.; Drullinsky, P.; Syldor, A.; Sujata, P.; more...
    Cancer Research (2011)

    Fulltext@MSK | Save